1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Mylan Still Mulling Revance's Botox Biosimilar

Firms Are Still In Discussions Despite Passing 30 April Deadline

 
• By Dave Wallace

Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.

Girl_Botox_Injection
Revance is still waiting for a decision from Mylan despite passing a key date • Source: Shutterstock

Revance Therapeutics says it is still waiting for a decision from Mylan on whether to proceed with a collaborative development project on a proposed biosimilar version of Allergan’s Botox (onabotulinumtoxinA), revealing that it remains in discussions with the generics firm despite a previously extended deadline for the decision having passed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.